SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

08 Nov 2021 Evaluate
A decrease of about -36.61% in the sales to Rs. 28831.80 millions was observed for the quarter ended September 2021. The sales stood at Rs. 45485.00 millions during the similar quarter previous year.A big loss of -75.19% reported for the quarter ended September 2021 to Rs. 1976.80  millions from Rs. 7969.30 millions.Operating profit for the quarter ended September 2021 decreased to 4221.00 millions as compared to 12506.90 millions of corresponding quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 28831.80 45485.00 -36.61 57769.30 79744.90 -27.56 158236.80 133707.70 18.35
Other Income 823.70 431.70 90.80 1263.20 1641.30 -23.04 5898.60 2434.30 142.31
PBIDT 4221.00 12506.90 -66.25 8768.60 23321.50 -62.40 47096.80 29412.90 60.12
Interest 34.40 64.50 -46.67 85.00 168.90 -49.67 286.80 979.10 -70.71
PBDT 4186.60 12442.40 -66.35 8683.60 23152.60 -62.49 46810.00 28433.80 64.63
Depreciation 981.80 1212.50 -19.03 2128.30 2417.10 -11.95 4879.90 4733.30 3.10
PBT 3204.80 11229.90 -71.46 6555.30 20735.50 -68.39 41930.10 23700.50 76.92
TAX 1228.00 3260.60 -62.34 2427.80 5690.90 -57.34 10801.00 4931.70 119.01
Deferred Tax 7.60 51.90 -85.36 -227.00 31.20 -827.56 367.60 8.80 4077.27
PAT 1976.80 7969.30 -75.19 4127.50 15044.60 -72.56 31129.10 18768.80 65.86
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 14.64 27.50 -46.76 15.18 29.25 -48.10 29.76 22.00 35.30

Aurobindo Pharma Share Price

1367.70 -17.95 (-1.30%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×